Clinical Trial: Cannabidiol as a New Intervention for Amphetamine Dependence

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Cannabidiol as a New Intervention for Amphetamine Dependence: A Proof-of-concept Study

Brief Summary:

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). Cannabidiol (CBD), the second most abundant component of cannabis, is known for its broad spectrum of physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly CBD has been shown to be potentially helpful in treating addiction, due to its effects on various neuronal circuits involved in this disorder.

The investigators overall hypothesis is that CBD is an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.


Detailed Summary:
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Current Primary Outcome: Brain acitivty assessed by fMRI [ Time Frame: 18 months ]

Brain reactivity will be measured during visualization of 1) fearful faces to measure the effect of CBD on stress-induced neuronal reactivity and 2) amphetamine cue-induced craving images to measure the effect of CBD on drug cue-induced craving and neuronal corresponding reactivity.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Centre hospitalier de l'Université de Montréal (CHUM)

Dates:
Date Received: October 27, 2016
Date Started: April 2017
Date Completion: October 2018
Last Updated: March 7, 2017
Last Verified: March 2017